NDATOPICALSHAMPOO
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPITROL (chloroxine) is a topical antidandruff shampoo approved in 1976 for the treatment of seborrheic dermatitis and dandruff. The drug is formulated as a shampoo and is applied directly to the scalp. It represents a mature, legacy dermatology product with established clinical utility in managing scalp conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); limited brand team scaling expected as patent protection erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CAPITROL currently has zero linked job openings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career growth on this product is limited; positions that do exist focus on brand defense and commercial maintenance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on CAPITROL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.